EUVIMEDEUVIMED entdecken
Crossref

The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer

Patricia G Lu iD, Yu-Hui H Chang, Chee-Chee Stucky, Alexandra Potter, George C Linderman, Chi-Fu Jeffrey Yang, Rahul Pannala, Nabil Wasif, Michelle A Anderson, Zhi Ven Fong

Journal of Surgical Oncology · 12.08.2026

DOI: 10.1002/jso.70361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 12.08.2026. Verfasst von Patricia G Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post‐pancreatectomy exocrine insufficiency is common after resection for pancreatic cancer and requires pancreatic enzyme replacement therapy (PERT). We sought to determine the out‐of‐pocket cost of PERT and the association between PERT and survival.

Methods

The SEER‐linked Medicare database was queried for patients with pancreatic cancer who underwent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) from 2010 to 2019. Cumulative out‐of‐pocket costs were calculated and stratified by procedure and radiation.

Results

11,854 Medicare beneficiaries with resected pancreatic cancer were identified, 4,653 (39%) required PERT and 7,201 (61%) did not. Median age was 73.0, 50.6% were female and 83.6% White. 25.9% underwent DP and 74.1% underwent PD; 7% received neoadjuvant radiation while 23.5% received adjuvant radiation. Logistic regression demonstrated that female sex (OR 1.25, 95% CI 1.16‐1.35, p < 0.001), neoadjuvant radiation (OR 1.93, 95% CI 1.67‐2.24, p < 0.001), and PD (OR 2.45, 95% CI 2.23‐2.7, p < 0.001) were risk factors for requiring PERT. Patients without subsidies who underwent DP paid a cumulative $4,736 out‐of‐pocket for PERT after 5 years, those who underwent PD paid $5,601 out‐of‐pocket.

Conclusions

Nearly 40% of Medicare beneficiaries took PERT after resection for pancreatic cancer and paid thousands in out‐of‐pocket costs. While a conservative estimate, these findings highlight the importance of addressing this financial burden to patients.

Schlagwörter

Stichwörter der Autor:innen

costdistal pancreatectomypancreas enzyme replacement therapypancreatic exocrine insufficiencypancreaticoduodenectomy

Autor:innen und Institutionen

  • Department of Surgery, Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Department of Quantitative Health Services, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
  • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Gastroenterology, Mayo Clinic Arizona, Phoenix, Arizona, USA.

ORCID-Profile: Patricia G Lu

Zitieren

APA

Lu, P. G., Chang, Y. H., Stucky, C. C., Potter, A., Linderman, G. C., Yang, C. J., Pannala, R., Wasif, N., Anderson, M. A., & Fong, Z. V. (2026). The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70361

Vancouver

Lu PG, Chang YH, Stucky CC, Potter A, Linderman GC, Yang CJ, et al. The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70361

BibTeX
@article{Lu2026,
  author = {Lu, Patricia G and Chang, Yu-Hui H and Stucky, Chee-Chee and Potter, Alexandra and Linderman, George C and Yang, Chi-Fu Jeffrey and Pannala, Rahul and Wasif, Nabil and Anderson, Michelle A and Fong, Zhi Ven},
  title = {The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70361}
}
Kostenlos starten →